Addictovigilance contribution during COVID-19 epidemic and lockdown in France

Grandvuillemin, 2020, French network of regional pharmacovigilance c. Adverse drug reactions of hydroxychloroquine: analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data, Therapies, 10.1016/j.therap.2020.05.001 Gerard, 2020, “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers, Therapies, 10.1016/j.therap.2020.05.002 Micallef, 2020, French Society of Pharmacology T. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection, Therapies, 10.1016/j.therap.2020.05.003 Larrouquere, 2020, Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic, Fundam Clin Pharmacol, 34, 389, 10.1111/fcp.12564 Jouanjus, 2015, Signal identification in addictovigilance: the functioning of the French system, Therapie, 70, 113, 10.2515/therapie/2015009 Jouanjus, 2017, Comment on: “Social media mining for toxicovigilance: automatic monitoring of prescription medication abuse from Twitter”, Drug Saf, 40, 183, 10.1007/s40264-016-0497-7 Jouanjus, 2019, Comment on: An insight into Z-drug abuse and dependence: an examination of reports to the European Medicines Agency database of suspected adverse drug reactions, Int J Neuropsychopharmacol, 22, 528, 10.1093/ijnp/pyz033 Baumevieille, 2019, From psychoactive medicines to addictovigilance in French Public Health Code (1990–2017), Therapies, 74, 375, 10.1016/j.therap.2018.07.007 Baumevieille, 2001, The French system of evaluation of dependence: establishment in a legal system, Therapie, 56, 15 Micallef, 2019, Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health, Therapies, 74, 579, 10.1016/j.therap.2019.09.005 Jouanjus, 2018, Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion, Fundam Clin Pharmacol, 32, 306, 10.1111/fcp.12356 Boeuf, 2007, Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey, Drug Saf, 30, 265, 10.2165/00002018-200730030-00007 Daveluy, 2018, Tamper-resistant prescription forms for narcotics in France: should we generalize them?, Fundam Clin Pharmacol, 32, 571, 10.1111/fcp.12368 Frauger, 2017, Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network, Therapie, 72, 491, 10.1016/j.therap.2017.01.010 Djezzar, 2009, Chemical submission: results of 4-year French inquiry, Int J Legal Med, 123, 213, 10.1007/s00414-008-0291-x Brisacier, 2019, 1 Dupui, 2019, Interest of large electronic health care databases in addictovigilance: lessons from 15 years of pharmacoepidemiological contribution, Therapies, 74, 307, 10.1016/j.therap.2018.09.078 Daveluy, 2020, Ten-year trend of opioid and non-opioid analgesic use in the French adult population, Br J Clin Pharmacol Auffret, 2019, A capture-recapture method for estimating the incidence of off-label prescriptions: the example of baclofen for alcohol use disorder in France, Therapies, 74, 645, 10.1016/j.therap.2019.06.002 Gentile, 2018, Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?, Fundam Clin Pharmacol, 32, 643, 10.1111/fcp.12401 Daveluy, 2018, Parachuting psychoactive substances: pharmacokinetic clues for harm reduction, Addict Behav, 78, 173, 10.1016/j.addbeh.2017.11.021 Peyriere, 2016, Medical complications of psychoactive substances with abuse risks: Detection and assessment by the network of French addictovigilance centres, Therapie, 71, 563, 10.1016/j.therap.2016.07.001 Batisse, 2020, Use of new psychoactive substances to mimic prescription drugs: The trend in France, Neurotoxicology, 79, 20, 10.1016/j.neuro.2020.03.015 Nguyen, 2017, Identifying Life-Threatening Admissions for Drug Dependence or Abuse (ILIADDA): derivation and validation of a model, Sci Rep, 7, 44428, 10.1038/srep44428 Moracchini, 2012, Les CAARUD, lieux privilégiés d’émergence de signaux pour l’addictovigilance, Therapie, 67, 437, 10.2515/therapie/2012064 Ministre des Solidarités et de la Santé, 2020, Arrêté du 19 mars 2020 complétant l’arrêté du 14 mars 2020 portant diverses mesures relatives à la lutte contre la propagation du virus COVID-19, JORF, 0069 Frauger, 2018, Intérêt de la mise à disposition de la naloxone auprès des usagers de drogues pour le traitement d’urgence de surdosage d’opioïdes, Therapie, 73, 511, 10.1016/j.therap.2018.07.001 Frauger, 2019, Améliorer la balance bénéfices/risques de la méthadone en respectant ses spécificités pharmacologiques, Therapies, 74, 383, 10.1016/j.therap.2018.09.070 Mengin, 2020, Psychopathological consequences of confinement, Encephale, 22 ANSM, 2020 Pauly, 2015, Detection of signals of abuse and dependence applying disproportionality analysis, Eur J Clin Pharmacol, 71, 229, 10.1007/s00228-014-1783-x Ponte, 2017, Early signal of diverted use of tropicamide eye drops in France, Br J Clin Pharmacol, 83, 1791, 10.1111/bcp.13272 Tournebize, 2019, Le mésusage du fentanyl en France : 2010 à 2015, Therapies, 25 Driot, 2016, Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history, Therapie, 71, 575, 10.1016/j.therap.2016.04.006 Driot, 2019, Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France, Br J Clin Pharmacol, 85, 1260, 10.1111/bcp.13892 Lapeyre-Mestre, 2015, Drug abuse monitoring: which pharmacoepidemiological resources at the European level?, Therapie, 70, 147, 10.2515/therapie/2015006 Micallef, 2020, Warning on increased serious health complications related to non-medical use of nitrous oxide, Therapies, 17 Jouanjus, 2012, Use of multiple sources and capture-recapture method to estimate the frequency of hospitalizations related to drug abuse, Pharmacoepidemiol Drug Saf, 21, 733, 10.1002/pds.3280 Frauger, 2011, Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network, Fundam Clin Pharmacol, 25, 633, 10.1111/j.1472-8206.2010.00882.x Peyriere, 2013, Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France, Eur Addict Res, 19, 235, 10.1159/000346179 Micallef, 2015, Example of an investigation of an “emergent” phenomenon in addiction vigilance: the case of methylphenidate, Therapie, 70, 191, 10.2515/therapie/2015012 Jouanjus, 2018, Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion, Fundam Clin Pharmacol, 32, 306, 10.1111/fcp.12356 Baumevieille, 2019, Pharmaciens d’officine, étudiants en pharmacie et demandes de médicaments à base de codéine: étude observationnelle, Therapies Bossard, 2016, Disproportionality analysis for the assessment of abuse and dependence potential of pregabalin in the French Pharmacovigilance database, Clin Drug Investig, 36, 735, 10.1007/s40261-016-0421-z Jouanjus, 2018, Detecting the diverted use of psychoactive drugs by adolescents and young adults: A pilot study, Pharmacoepidemiol Drug Saf, 27, 1286, 10.1002/pds.4624 Addictovigilance, 2020